Bio-Techne Appoints New President of Genomics, Diagnostics Division By Investing.com
© Reuters.
MINNEAPOLIS – Bio-Techne (NASDAQ:) Corporation (NASDAQ:TECH), a global life sciences company, has appointed Matthew F. McManus as President, Diagnostics and Genomics, effective January 8, 2024. This announcement was made as part of: This is a leadership transition that will see Kim Kelderman, the current Chief Operating Officer (COO), assume the position of Chief Executive Officer (CEO) on February 1, 2024.
Dr. McManus comes to his new role with over 20 years of experience in the life sciences industry. During his most recent tenure, he served as Executive Vice President and Chief Operating Officer at Azenta, where he oversaw the company’s life sciences products, services and commercial operations. He received his Ph.D. from Bio-Techne. After acquiring Asuragen, where McManus served as president and CEO, he previously led the company’s molecular diagnostics division.
His academic qualifications are notable as MD and Ph.D. He earned a bachelor’s degree from the University of Pennsylvania School of Medicine, an MBA from Boston College, and a bachelor’s degree in economics from the College of the Holy Cross. Additionally, he currently serves as Chairman of the Board of Directors of ANSA, a company engaged in gene synthesis and cell and gene therapy markets.
Kim Kelderman expressed confidence in the appointment of Dr. McManus, stating that his previous success at Bio-Techne and extensive experience in the life sciences make him well positioned to lead the Diagnostics and Genomics division into its next phase of growth.
Bio-Techne specializes in developing, manufacturing and selling innovative, high-quality life science reagents, instruments and services for research, diagnostics and bioprocessing. The company’s commitment to providing high-quality products and services has made it a trusted partner to the global life sciences community.
The content of this article was written based on the press release.
This article was sponsored by AI and reviewed by an editor. Please see our T&Cs for more details.
